ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
作者信息
Lee Kristy, Abul-Husn Noura S, Amendola Laura M, Brothers Kyle B, Chung Wendy K, Gollob Michael H, Gordon Adam S, Harrison Steven M, Hershberger Ray E, Li Marilyn, Ondrasik Deborah, Richards C Sue, Stergachis Andrew, Stewart Douglas R, Martin Christa Lese, Miller David T
机构信息
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Department of Medicine, Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY; 23andMe Inc, Sunnyvale, CA.
出版信息
Genet Med. 2025 Aug;27(8):101454. doi: 10.1016/j.gim.2025.101454. Epub 2025 Jun 23.
Abstract
摘要
相似文献
1
ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会（ACMG）关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.3列表：一项政策声明
Genet Med. 2025 Aug;27(8):101454. doi: 10.1016/j.gim.2025.101454. Epub 2025 Jun 23.
2
ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会（ACMG）关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.1清单：一项政策声明
Genet Med. 2022 Jul;24(7):1407-1414. doi: 10.1016/j.gim.2022.04.006. Epub 2022 Jun 17.
3
ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).ACMG SF v3.2 临床外显子组和基因组测序中报告次要发现的列表：美国医学遗传学与基因组学学会 (ACMG) 的政策声明。
Genet Med. 2023 Aug;25(8):100866. doi: 10.1016/j.gim.2023.100866. Epub 2023 Jun 22.
4
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG).临床外显子组和基因组测序中次要发现报告的建议，2021年更新：美国医学遗传学与基因组学学会（ACMG）政策声明
Genet Med. 2021 Aug;23(8):1391-1398. doi: 10.1038/s41436-021-01171-4. Epub 2021 May 20.
5
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会（ACMG）关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.0清单：一项政策声明
Genet Med. 2021 Aug;23(8):1381-1390. doi: 10.1038/s41436-021-01172-3. Epub 2021 May 20.
6
Correspondence on "ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)" by Miller et al.米勒等人就“美国医学遗传学与基因组学学会（ACMG）关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.0清单：政策声明”的通信
Genet Med. 2022 Mar;24(3):744-746. doi: 10.1016/j.gim.2021.10.020. Epub 2021 Nov 30.
7
Correction to: ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).对《美国医学遗传学与基因组学学会（ACMG）关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.0列表：政策声明》的勘误
Genet Med. 2021 Aug;23(8):1582-1584. doi: 10.1038/s41436-021-01278-8.
8
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.临床外显子组和基因组测序中次要发现报告的建议，2016年更新版（美国医学遗传学与基因组学学会次要发现v2.0）：美国医学遗传学与基因组学学会政策声明
Genet Med. 2017 Feb;19(2):249-255. doi: 10.1038/gim.2016.190. Epub 2016 Nov 17.
9
Secondary Findings from Exome Sequencing of a Greek Cohort.希腊队列外显子组测序的次要发现
Curr Issues Mol Biol. 2025 Apr 11;47(4):272. doi: 10.3390/cimb47040272.
10
Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG).在选择次要发现基因-疾病对时对疾病外显率的考量：美国医学遗传学与基因组学学会（ACMG）的政策声明
Genet Med. 2024 Jul;26(7):101142. doi: 10.1016/j.gim.2024.101142. Epub 2024 May 31.
引用本文的文献
1
Secondary findings in pediatric genomic testing: clinical insights from Turkey.儿科基因组检测中的次要发现：来自土耳其的临床见解。
Eur J Pediatr. 2025 Aug 29;184(9):584. doi: 10.1007/s00431-025-06415-y.
本文引用的文献
1
Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 study.鹅去氧胆酸（CDCA）在成人脑腱性黄瘤病患者中的疗效、安全性及耐受性（RESTORE）：一项随机撤药、双盲、安慰剂对照、交叉3期研究。
Genet Med. 2025 Jul;27(7):101449. doi: 10.1016/j.gim.2025.101449. Epub 2025 Apr 25.
2
Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG).在选择次要发现基因-疾病对时对疾病外显率的考量：美国医学遗传学与基因组学学会（ACMG）的政策声明
Genet Med. 2024 Jul;26(7):101142. doi: 10.1016/j.gim.2024.101142. Epub 2024 May 31.
3
Natural history study of patients with familial platelet disorder with associated myeloid malignancy.家族性血小板疾病伴相关髓系恶性肿瘤患者的自然史研究。
Blood. 2023 Dec 21;142(25):2146-2158. doi: 10.1182/blood.2023019746.
4
ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).ACMG SF v3.2 临床外显子组和基因组测序中报告次要发现的列表：美国医学遗传学与基因组学学会 (ACMG) 的政策声明。
Genet Med. 2023 Aug;25(8):100866. doi: 10.1016/j.gim.2023.100866. Epub 2023 Jun 22.
5
Deficiency of adenosine deaminase 2 (DADA2): Review.腺苷脱氨酶2缺乏症（DADA2）：综述
Best Pract Res Clin Rheumatol. 2023 Mar;37(1):101844. doi: 10.1016/j.berh.2023.101844. Epub 2023 Jun 15.
6
Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement.腺苷脱氨酶 2 缺乏症的评估和管理：国际共识声明。
JAMA Netw Open. 2023 May 1;6(5):e2315894. doi: 10.1001/jamanetworkopen.2023.15894.
7
ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会（ACMG）关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.1清单：一项政策声明
Genet Med. 2022 Jul;24(7):1407-1414. doi: 10.1016/j.gim.2022.04.006. Epub 2022 Jun 17.
8
The Spectrum of the Deficiency of Adenosine Deaminase 2: An Observational Analysis of a 60 Patient Cohort.腺苷脱氨酶 2 缺乏症的谱：60 例患者队列的观察性分析。
Front Immunol. 2022 Jan 10;12:811473. doi: 10.3389/fimmu.2021.811473. eCollection 2021.
9
Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction.磷酸化酶脑肌磷酸酶辅因子 1 基因 p.Arg14del 突变携带者室性心律失常的预测——个体风险预测的前沿。
Eur Heart J. 2021 Jul 31;42(29):2842-2850. doi: 10.1093/eurheartj/ehab294.
10
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG).临床外显子组和基因组测序中次要发现报告的建议，2021年更新：美国医学遗传学与基因组学学会（ACMG）政策声明
Genet Med. 2021 Aug;23(8):1391-1398. doi: 10.1038/s41436-021-01171-4. Epub 2021 May 20.
Zotero 插件